Thomas Hogan - Cellebrite Executive Chairman
| CLBT Stock | USD 19.72 0.46 2.28% |
Chairman
Thomas Hogan is Executive Chairman of Cellebrite DI
| Age | 65 |
| Address | 94 Shlomo Shmelzer Road, Petah Tikva, Israel, 4970602 |
| Phone | 972 73 394 8000 |
| Web | https://www.cellebrite.com |
Thomas Hogan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas Hogan against Cellebrite stock is an integral part of due diligence when investing in Cellebrite. Thomas Hogan insider activity provides valuable insight into whether Cellebrite is net buyers or sellers over its current business cycle. Note, Cellebrite insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cellebrite'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas Hogan over three months ago Acquisition by Thomas Hogan of 156 shares of Perficient subject to Rule 16b-3 | ||
Thomas Hogan over six months ago Disposition of 4657 shares by Thomas Hogan of Perficient at 69.1 subject to Rule 16b-3 | ||
Thomas Hogan over six months ago Acquisition by Thomas Hogan of tradable shares of Perficient subject to Rule 16b-3 |
Cellebrite Management Efficiency
The company has return on total asset (ROA) of 0.0635 % which means that it generated a profit of $0.0635 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.885) %, meaning that it created substantial loss on money invested by shareholders. Cellebrite's management efficiency ratios could be used to measure how well Cellebrite manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.12 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.15). Total Current Liabilities is likely to drop to about 199.5 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 424.2 M in 2024Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Frank DAngelo | Evertec | 73 | |
Management Performance
| Return On Equity | -1.88 | ||||
| Return On Asset | 0.0635 |
Cellebrite DI Leadership Team
Elected by the shareholders, the Cellebrite's board of directors comprises two types of representatives: Cellebrite inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellebrite. The board's role is to monitor Cellebrite's management team and ensure that shareholders' interests are well served. Cellebrite's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellebrite's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yossi Carmil, CEO Founder | ||
| Thomas Hogan, Executive Chairman | ||
| Zohar TadmorEilat, Chief Officer | ||
| Osnat Tirosh, Chief Officer | ||
| David Gee, Chief Officer | ||
| Adam Jaffe, VP Communications | ||
| Ayala Shapira, General Counsel | ||
| Marque Teegardin, President Management | ||
| Ronnen Armon, Chief Officer | ||
| Arnon Zilberman, Executive Operations | ||
| Andrew Kramer, Vice Relations | ||
| Dana Gerner, Chief Officer | ||
| Paul Battaglia, Sr America | ||
| Lisa Cole, Chief Officer | ||
| Leeor BenPeretz, Chief Officer | ||
| Anat EaronHeilborn, VP Relations | ||
| Marcus Jewell, Global Officer |
Cellebrite Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cellebrite a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.88 | ||||
| Return On Asset | 0.0635 | ||||
| Profit Margin | (0.82) % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 3.88 B | ||||
| Shares Outstanding | 214.84 M | ||||
| Shares Owned By Insiders | 46.79 % | ||||
| Shares Owned By Institutions | 52.99 % | ||||
| Number Of Shares Shorted | 1.51 M | ||||
| Price To Earning | 82.18 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cellebrite Stock Analysis
When running Cellebrite's price analysis, check to measure Cellebrite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellebrite is operating at the current time. Most of Cellebrite's value examination focuses on studying past and present price action to predict the probability of Cellebrite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellebrite's price. Additionally, you may evaluate how the addition of Cellebrite to your portfolios can decrease your overall portfolio volatility.